You have 9 free searches left this month | for more free features.

JAK inhibitor

Showing 1 - 25 of 6,468

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

Abatacept, Treatment Compliance, Rheumatoid Arthritis Trial in Hangzhou (Janus Kinase Inhibitor, Abatacept)

Recruiting
  • Abatacept
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Provincial People's Hospital
Jul 5, 2022

Rheumatoid Arthritis Patients Treated With JAK-inhibitor

Recruiting
  • Rheumatoid Arthritis
  • Upadacitinib <15 MG [Rinvoq]
  • Montpellier, France
    CHU de Montpellier
Jan 12, 2022

Dermatomyositis, Adult Type Trial in Xi'an (JAK Inhibitor)

Recruiting
  • Dermatomyositis, Adult Type
  • JAK Inhibitor
  • Xi'an, Shaanxi, China
    Department of Rheumatology, the First Affiliated Hospital of Xi'
Jul 15, 2021

Rheumatoid Arthritis Trial (Upadacitinib, Adalimumab)

Not yet recruiting
  • Rheumatoid Arthritis
  • (no location specified)
Nov 29, 2021

Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor Trial in Nagasaki (filgotinib 200mg/day, subcutaneous tocilizumab

Recruiting
  • Rheumatoid Arthritis
  • +4 more
  • filgotinib 200mg/day
  • subcutaneous tocilizumab 162mg/biweekly
  • Nagasaki, Japan
    Nagasaki University Hospital
Oct 23, 2021

Primary Myelofibrosis, Secondary Myelofibrosis Trial in Greifswald, Halle (Saale) (Fedratinib Oral Capsule [Inrebic], Nivolumab)

Recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Greifswald, Germany
  • +1 more
Jun 15, 2022

Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondyloarthritis Trial in Caba, Ciudad Autonoma Buenos Aires (DMARDs, biologic

Recruiting
  • Arthritis, Rheumatoid
  • +2 more
  • Caba, Buenos Aires, Argentina
  • +1 more
Mar 26, 2021

Myelofibrosis Trial in Worldwide (Ruxolitinib)

Completed
  • Myelofibrosis
  • Winter Park, Florida
  • +17 more
Jan 10, 2022

Graft-versus-host-disease, Graft Vs Host Disease Trial in Saint Louis (Baricitinib)

Recruiting
  • Graft-versus-host-disease
  • Graft Vs Host Disease
  • Saint Louis, Missouri
    Washington University School of Medicine
Mar 4, 2022

Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome Trial in Seattle (Decitabine, Ruxolitinib,

Recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Feb 25, 2022

Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound Trial in Nagasaki (upadacitinib 15mg/day)

Recruiting
  • Rheumatoid Arthritis
  • +3 more
  • upadacitinib 15mg/day
  • Nagasaki, Japan
    Nagasaki University Hospital
Nov 24, 2021

Myelofibrosis Trial in Canton (Jaktinib Hydrochloride Tablet)

Not yet recruiting
  • Myelofibrosis
  • Jaktinib Hydrochloride Tablet
  • (no location specified)
Mar 3, 2022

Cicatricial Alopecia Trial in New York (PF-06700841, Placebo)

Recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 16, 2022

Rheumatoid Arthritis Trial in Abu Dhabi (Anti-TNF, JAK inhibitor)

Not yet recruiting
  • Rheumatoid Arthritis
  • Abu Dhabi, United Arab Emirates
    Abu Dhabi Stem Cells Center
May 17, 2022

BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of

Recruiting
  • BCR-JAK2 Fusion Protein Expression
  • +11 more
  • Palo Alto, California
  • +1 more
Nov 12, 2021

Myelofibrosis Trial in Houston (Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib)

Active, not recruiting
  • Myelofibrosis
  • Long-term Follow-up
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Hematopoietic and Lymphoid Cell Tumor, Steroid Refractory GVHD Trial in Houston (Cellular Therapy, Ruxolitinib)

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Steroid Refractory Graft Versus Host Disease
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Chronic Hand Dermatitis Trial in Rochester (Ruxolitinib)

Recruiting
  • Chronic Hand Dermatitis
  • Rochester, New York
    UR Medicine Dermatology College Town
Aug 9, 2022

Myelofibrosis Trial in Worldwide (Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg)

Completed
  • Myelofibrosis
  • Imetelstat 4.7 mg/kg
  • Imetelstat 9.4 mg/kg
  • Birmingham, Alabama
  • +71 more
Aug 17, 2021

Recurrent Classical Hodgkin Lymphoma Trial in Cologne (Ruxolitinib)

Completed
  • Recurrent Classical Hodgkin Lymphoma
  • Cologne, Germany
    1st Dept. of Medicine, Cologne University Hospital
Apr 3, 2020

Vitiligo, Effect of Drug Trial (JAK-2 inhibitor, Topical corticosteroid)

Not yet recruiting
  • Vitiligo
  • Effect of Drug
  • JAK-2 inhibitor
  • Topical corticosteroid
  • (no location specified)
Mar 19, 2022

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, MDS Trial in Saint Louis (procedure, drug, other)

Recruiting
  • Acute Myelogenous Leukemia
  • +4 more
  • Stem cell transplantation
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 23, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia Trial in Houston (Ruxolitinib,

Completed
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Untreated Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Mar 23, 2021

Cicatricial Alopecia Trial in New York (PF-06651600)

Not yet recruiting
  • Cicatricial Alopecia
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Sep 19, 2022